According to a news release posted on the official website of the U.S. Food and Drug Administration (FDA) on October 15, leaders from the National Institutes of Health (NIH) and FDA emphasized the importance of advancing research and development for smoking cessation treatments in a new commentary published in the Annals of Internal Medicine. The authors of the article updated regulatory pathways for smoking cessation treatments and outlined innovative treatment targets, research gaps, and development opportunities. They stressed the crucial role of active participation from clinical physicians, academia, industry, public health agencies, patient groups, and other stakeholders.
Data shows that nearly 500,000 people die from smoking in the United States each year, with over 28 million adults smoking in the country. While most smokers express a desire to quit, only 31% of those intending to quit actually seek counseling or medication treatment. The success rate for quitting smoking each year is less than 8%.
The commentator proposed solutions to these issues, including recommendations from the FDA 2023 Nicotine Replacement Therapy guidelines. In order to inspire innovation in smoking cessation product development, the commentator suggested that in smoking cessation trials, in addition to focusing on abstinence, meaningful endpoints should also be considered, such as clinically significant reduction in smoking, especially if this reduction increases the likelihood of eventual cessation.
The authors also emphasized the urgent need for more in-depth research on e-cigarettes, including long-term health outcomes and rigorous toxicology studies. They also discussed programs being conducted by the NIH and FDA aimed at promoting innovative research on smoking cessation, particularly targeting underrepresented groups in historical research trials.
This commentary was released prior to the joint public meeting of the FDA and NIH on advancing smoking cessation priorities, which is scheduled to take place on October 21 from 9:00 AM to 4:30 PM (Eastern Time).
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
